Thymogen (Oglufanide)
Also known as: Glu-Trp, Thymagen
Thymogen (Oglufanide), also called Glu-Trp or Thymagen, is a thymic dipeptide. Thymogen is Glu-Trp, a synthetic dipeptide identified as an active fragment of thymopoietin and also known as oglufanide. Despite its very small size it is reported to modulate T-cell differentiation and to influence innate immune responses, with described effects on neutrophil and macrophage function and on cytokine production.
For research use only.
Key Facts
- CAS
- 148698-17-5
- Molecular Weight (MW)
- 333.34 g/mol
- Half-life
- Not firmly established (small dipeptide)
- FDA status
- Not Approved
- Administration Route
- —
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Immune cells (proposed)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected in Oct 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 9
- Listed offers
- 11
- Median price per mg
- $4.00/mg
- Typical $3.25–$5.46/mg
Research summary
Glu-Trp, a synthetic dipeptide identified as the active fragment of thymopoietin and also known as oglufanide. Despite its very small size it has been studied as an immunomodulator affecting T-cell differentiation and innate immune function, and is used in some CIS markets for that purpose. Its plasma half-life is measured in minutes, which constrains how it can be given. Not FDA-approved.
Peptide Library's Thymogen (Oglufanide) profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Per study/label outside U.S.; not FDA-approved
- Frequency
- —
- Cycle
- —
- Administration Route
- —
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Thymogen (Oglufanide) is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C16H19N3O5 |
|---|---|
| Molecular weight | 333.34 g/mol |
| CAS number | 148698-17-5 |
| Half-life | Not firmly established (small dipeptide) |
| Appearance | White lyophilized powder or solution (research) |
| Formulation | Lyophilized Powder |
| PubChem CID | 100094 |
| FDA UNII | 4RHY598T5U |
| ChEMBL | CHEMBL2111029 |
| DrugBank | DB05779 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Thymogen is Glu-Trp, a synthetic dipeptide identified as an active fragment of thymopoietin and also known as oglufanide. Despite its very small size it is reported to modulate T-cell differentiation and to influence innate immune responses, with described effects on neutrophil and macrophage function and on cytokine production. It has been studied as an immunomodulator in infection and as an adjunct in oncology and hepatitis research. As with other short peptides its plasma half-life is very short, which constrains dosing. The supporting literature is largely regional, and it has no FDA-approved use.
Origin
Synthetic Glu-Trp.
Targets
Studies
- The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples
- Hepatoprotective Effects of Thymogen Analogues in Hydrazine Hepatopathy in Rats
- Cy5.5-8-Amino-octanoic acid-Ser-Cys-Pro-Pro-Trp-Gln-Glu-Trp-His-Asn-Phe-Met-Pro-Phe-NH(2)
- Whey Protein Peptide Pro-Glu-Trp Ameliorates Hyperuricemia by Enhancing Intestinal Uric Acid Excretion, Modulating the Gut Microbiota, and Protecting the Intestinal Barrier in Rats
- Reparative and Antioxidant Effects of New Analogues of Immunomodulator Thymogen in Experimental Model of Liver Damage
Regulatory & research status
Thymogen (Oglufanide) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
Thymogen (Oglufanide) side effects
Side Effects
- Not well characterized in FDA-standard trials
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Thymogen (Oglufanide): frequently asked questions
What is Thymogen (Oglufanide)?
Glu-Trp, a synthetic dipeptide identified as the active fragment of thymopoietin and also known as oglufanide. Despite its very small size it has been studied as an immunomodulator affecting T-cell differentiation and innate immune function, and is used in some CIS markets for that purpose. Its plasma half-life is measured in minutes, which constrains how it can be given. Not FDA-approved.
How does Thymogen (Oglufanide) work?
Thymogen is Glu-Trp, a synthetic dipeptide identified as an active fragment of thymopoietin and also known as oglufanide. Despite its very small size it is reported to modulate T-cell differentiation and to influence innate immune responses, with described effects on neutrophil and macrophage function and on cytokine production.
Is Thymogen (Oglufanide) FDA approved?
No. Thymogen (Oglufanide) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Thymogen (Oglufanide)?
Reported half-life for Thymogen (Oglufanide) is Not firmly established (small dipeptide). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What peptides are similar to Thymogen (Oglufanide)?
Compounds most often compared with Thymogen (Oglufanide) include Thymosin Alpha-1, Thymalin, Thymopentin and Thymulin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples — Int J Mol Sci, 2024External reference
- Hepatoprotective Effects of Thymogen Analogues in Hydrazine Hepatopathy in Rats — Bull Exp Biol Med, 2025External reference
- Cy5.5-8-Amino-octanoic acid-Ser-Cys-Pro-Pro-Trp-Gln-Glu-Trp-His-Asn-Phe-Met-Pro-Phe-NH(2), 2004External reference
- Whey Protein Peptide Pro-Glu-Trp Ameliorates Hyperuricemia by Enhancing Intestinal Uric Acid Excretion, Modulating the Gut Microbiota, and Protecting the Intestinal Barrier in Rats — J Agric Food Chem, 2024External reference
- Reparative and Antioxidant Effects of New Analogues of Immunomodulator Thymogen in Experimental Model of Liver Damage — Bull Exp Biol Med, 2023External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Thymogen (Oglufanide) profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Thymogen (Oglufanide) research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →